Osteoarthritis advances: AI-driven drug candidate and expert care guidance

Researchers at the University of Utah Health combined genetic studies of hereditary osteoarthritis families with artificial‑intelligence tools to narrow half a million potential compounds to six candidates in weeks. Using an AI‑predicted structure of the WNK2 protein, they identified a compound called M04 that reduced inflammation‑related genes and protected cartilage cells in a laboratory model, suggesting a new avenue for disease‑modifying treatment.

Separately, Dr. Christine Peoples of UPMC’s Telerheumatology Program outlined practical advice for managing osteoarthritis, noting that one in five adults lives with chronic pain and that joint issues become common after age 40. She emphasized when to seek medical care, the role of genetics (accounting for 40‑80% of risk), and the benefits of regular moderate exercise such as walking, cycling or swimming to maintain joint health and reduce stiffness.